Contents

3 A message from the Chair Barbara Harpham
4 Strategic Aims
5 Highlights of the Year
8 Achievements of the Year
9 Looking Forwards
11 Medical Technology and Society
A message from the Chair
Barbara Harpham

It is a great privilege to chair the Medical Technology Group (MTG), the only UK coalition of industry groups and patient charities working together to improve patient access to medical technologies, and heartening to see the strides we are making in our campaigns to highlight how much of a benefit innovative medical technologies can make to patients’ day-to-day lives.

It is an exciting time for the MTG, as membership continues to grow along with the group’s profile and reach. It is fantastic to see such a growth in the number of patient charities and industry groups working together to shine a spotlight on the beneficial treatment options innovative medical technology provides for patients with a range of both acute and long-term conditions.

Medical Technology Awareness Week, which is held annually, is always a particular highlight of mine as well as for many of the group’s members. The Parliamentary Reception held during this week is the showcase event, which celebrates the role that medical technology has played in supporting the NHS and patients, and is a great opportunity for charities, patient groups and industry representatives to present a range of technologies and discuss with attendees the benefits and current barriers to wider patient access. It is a fantastic way of getting people to talk about medical technology and the great potential it has to make a difference.

In recent years the group’s focus has taken into consideration the financial pressures the NHS is under, particularly as the health service tries to meet substantial efficiency savings targets. In such a climate it has therefore also been important for the group to highlight that not only can improved patient access to medical technology deliver improved patient outcomes, but that improved patient access can also deliver savings for the NHS, as well as more widely.

The group has therefore taken significant steps to highlight medical technology’s potential to generate efficiency savings in the NHS at a time when it is most needed and of the most importance and will continue to do so going forward. That the UK is one of the slower developed countries to adopt new medical technologies means that many of the benefits of improved quality and patient outcomes are currently not being realised. It seems clear to the MTG that there is a lot of work still to do to ensure that patients maintain equitable access to innovative medical treatments, as recommended by NICE where clinically appropriate, wherever they live in the UK.

The upcoming year will see the group continue to campaign for technologies with a proven benefit to patients and NHS productivity to be spread throughout the NHS. I am very much looking forward to all the work the group has planned for the rest of 2016 and to celebrating the group’s continuing contribution to the delivery of life changing innovations that make a real difference to patients’ everyday lives.

The MTG is the only UK coalition of industry groups and patient charities working together to improve patient access to medical technologies. The MTG believes that patients and clinicians need better information about medical technologies so that they can make informed choices about their medical care, which in turn will benefit the NHS, improve patient outcomes and reduce costs.
Strategic Aims

MTG Campaign Pillars

1. **Equity of Access** – To establish equality of access for all patients in all CCG areas to medical technologies irrespective of where they live.

2. **Linking Decision Making to Longer Term Value** – To change the perception that medical technology only adds cost to the system, by raising awareness of the evidence that investment leads to savings in the long run. We want to ensure that value rather than cost is used in making investment decisions in the NHS and to promote intelligent decision-making.

3. **Better Information & Education** – Clinicians and commissioners should be kept up-to-date with developments in medical devices to ensure that they refer patients appropriately. In addition, the NHS should be encouraged to do more to fully inform patients of the range of treatment options available.

2016 MTG Objectives

1. **Thought leadership and media impact** – for the MTG to become known as the organisation to come to for quotes and feedback on new issues, debates and reports and to be regularly releasing articles and being mentioned in the media.

2. **Engage and influence** – to engage and influence key stakeholders both at parliament and in the NHS.
Highlights of the Year

April 2015
Jason Stamp Addresses MTG members

Jason Stamp, Chair of the Patient and Public Voice Assurance Group (PPVAG) spoke to the MTG about the work of the PPVAG as a critical friend to NHS England and some of the challenges they face in engaging with specialised commissioning. After the event Jason Stamp wrote a short blog which you can read here: www.mtg.org.uk/press-releases/improving-specialised-commissioning.

June 2015
MTG Parliamentary Researchers Forum

A drink’s reception for parliamentary staff was held on June 27th in the Old Star in Westminster. Over 20 Parliamentary advisors, senior staff and researchers attended the event and met with patients and industry members. The reception was a great opportunity to build relationships with researchers, promote greater understanding of the medical device industry and ask how the MTG may best pursue its aims in Westminster.

July 2015
Dilip Chauhan’s Presentation and Q&A to the MTG

Dilip Chauhan spoke to the group about the work of the Office for Life Sciences (OLS) before highlighting possible areas of partnership between the MTG and the OLS. In particular he highlighted the Accelerated Access Review (AAR), Med Tech Sector Council and the Carter Review.

November 2015
Unplanned Admissions Spotlight Campaign

The spotlight campaign on unplanned admissions was launched during Medical Technology Week in November 2015. The report shone a spotlight on rates of unplanned admissions focusing on three areas: urinary tract infections, heart failure and diabetes. Report findings show that there are major savings to be made (approximately £1billion) in reducing unplanned admissions. Follow up has since taken place around the report, which included meetings with parliamentarians, the Rt Hon Dr Liam Fox MP and the office of the Rt Hon Keith Vaz MP to discuss key areas identified within the report.
November 2015
Medical Technology Week 2015

The Medical Technology Group’s 2015 parliamentary reception was hosted by John Pugh MP and was once again the showcase event of Medical Technology Awareness Week. Over 150 parliamentarians, patient users, patient groups, industry members, healthcare professionals, commissioners and representatives from the NHS and other Government departments came together to discuss issues surrounding medical technologies, current barriers to uptake and the benefits of medical technology in both reducing costs to the NHS and improving patient outcomes.

The aim of this annual awareness week is to get people talking about medical technology and the great potential it has to make a difference to patients’ everyday lives. This year, the week also aimed to highlight medical technology’s potential to generate efficiency savings in the NHS at a time when it is most needed and of the most importance. The UK is one of the slower developed countries to adopt new medical technologies, which means that many of the benefits of improved quality and patient outcomes are currently not being realised.

The focus of this year’s reception was on how far medical technology has progressed in the past 50 years and its future potential and value. The themed showcase had both medical technology devices from the past and the latest technology in use today on display, which highlighted some of the huge advancements made and the potential for medical technology to innovate further and be of even greater value to patients and health services.

The showcase included displays of medical technology throughout the body from head to toe. Technology on display included thoracic stents, heart valves, ICDs, pacemakers, insulin pumps, hip and knee replacement technology, vascular stents and balloons, woundcare products, and InVivo diagnostics.

Attendees learnt about each of the technologies from charities, patient groups and industry representatives, who were at each stand to give further information and to discuss with attendees the benefits and current barriers to wider patient access.

Over 20 parliamentarians attended the reception and signed our parliamentary pledge calling for better patient across to medical technology across the UK.
March 2016
Professor Tim Briggs Speaks to MTG Members

Professor Tim Briggs, National Director for Clinical Quality and Efficiency at the Department of Health, met MTG members on 10th March to discuss the Carter Review and the implementation of its recommendations. Professor Briggs confirmed his support of innovative medical technology that can make a real difference to patient outcomes and reduce bed days, but stressed the need for the durability and efficacy of technologies to be proven before being rolled out across the NHS.

He emphasised that the NHS is under considerable financial pressures and therefore new procedures and technologies need to demonstrate that they are cost effective and better value than procedures that are already available. After the event Professor Briggs wrote a short blog which you can read here: www.mtg.org.uk/girft.

July 2016
CtE Parliamentary Breakfast Meeting

The latest all members meeting was held on 13th July and focused on NHS England’s Commissioning through Evaluation (CtE) programme. Derek Thomas, MP for St Ives and member of the Science and Technology Committee, hosted the event in Parliament and was joined by fellow parliamentarians Jo Churchill and Lord Hunt of Kings Heath to discuss the programme with those in attendance.

MTG members first heard from three clinicians on specific procedures included in the programme, before then hearing from James Palmer and Ann Jarvis, Clinical Director of Specialised Commissioning and Acute Portfolio Director (Specialised Services) from NHS England respectively. They gave more information about the programme and what the future holds for the programme, as well as patient access to innovative treatment within the NHS more generally. An open discussion and Q&A session followed.
Achievements of the Year

Twitter: More than 550 followers
(including MPs and policy makers, clinicians, medical technology industry, patient groups, and media)
Potential Twitter reach since October 2013: 600,000+

MTG in the Media
15 articles in specialist media in 2015.
Over 300 items of media coverage in national, regional, specialist, and online media since November 2013.

Medical Technology Group Wikipedia page:
2000+ views

4 New Members in 2015:

Influencing the Accelerated Access Review
The MTG responded to the consultation on the Accelerated Access Review and the MTG is now a registered stakeholder for this work moving forwards.

Other Consultation Responses
The MTG responded to the NHS England and Monitor consultation on Tariff Proposals for 2016/17. The MTG also responded to the Clinical Reference Groups consultation, and the National Tariff consultation, the most recent PROMS consultation and a consultation on specialised commissioning.
Looking Forwards

Medical Technology Week 2016

It has been confirmed that Medical Technology Week 2016 will take place from 5th-9th December this year.

The Parliamentary Reception will be held on Tuesday 6th December 2016 in the Terrace Pavillion, House of Commons, with Jo Churchill MP hosting the event. Ms Churchill is the Chair of the new All-Party Parliamentary Group (APPG) on Personalised Medicine, which aims to help the NHS and patients make best use of the increasing availability of cutting-edge technologies to provide more personalised health and care. She hosted the lunch that formed part of Medical Technology Week last year.

The reception always attracts a strong attendance with many parliamentarians stopping by, several MTG members showcasing technology and a wide range of attendees. The reception is a good example of attendees and MTG members coming together at Parliament to raise issues around medical technology.

Further details for Medical Technology Week 2016 will be communicated shortly. For further information please email mtg@pbpoliticalconsulting.com.

Innovation in the NHS

The group’s most recent spotlight campaign, entitled ‘Deja Review: What lessons can we learn from the past?’, was launched in June 2016 and focuses on innovation in the NHS.

Improving the way the NHS uses innovation has become the holy grail of NHS efficiency, however many would argue that, despite a series of initiatives and reports promoting better use of innovation, the NHS remains a ‘late and slow adopter of innovation’, as Dereck Wanless described the NHS in 2004 in his review, ‘Securing Good Health for the Whole Population’.  

With the publication of the Accelerated Access Review (AAR) in mind, which will put forward a range of new measures aimed at addressing an old problem, the MTG has looked at what can be learnt from previous initiatives and suggest ways the AAR can have most impact.

The areas the MTG believes the AAR should focus on include:
- Learning from previous innovation reports
- Committing to a long term programme
- Applying the available evidence
- Breaking down budgetary barriers and incentivising innovation
- Focusing on implementation.

The full report can be accessed here: www.drive.google.com/file/d/0B60cHNIWGkbiSzJaN29tdXB3ZmM/view

The Work Foundation Report Update

The group’s next spotlight campaign will focus on updating the report 'The Economic and Societal Benefits of Medical Technology', which was funded by a research grant from the MTG. The 2011 report can be accessed here: http://www.mtg.org.uk/reports

The report identified three key areas of benefits from medical technologies:

- Improvements in health care (quality, efficiency and the empowerment of patients)
- Improving quality of life and independent living (reducing fears and anxiety, increasing flexibility, and reducing the need for informal care and the burden on informal caregivers)
- Labour market participation and productivity (increasing labour market participation, retaining skills and improving productivity)

The update aims to provide fresh data and information to support the group’s campaign to improve patient access to innovative medical technology and treatments. The report will not only update existing information for technologies covered in the original report but also look at a number of new technologies and other clinical areas.

The report will include patient case studies as well as make European and international comparisons. The report will be launched during this year’s Medical Technology Week, which is taking place from 5th - 9th December 2016.
**Medical Technology and Society**

- **15 million** people live with a long-term condition in England alone.
- **Over 70%** of all UK health and social care spending goes on long-term conditions.
- **30 million** people in the UK with long-term conditions expected by 2050.

**500,000 different medical technologies are available (including medical devices, in vitro diagnostics, imaging equipment and e-health).**

**Medical technology**

- Can improve patients’ lives, reduce healthcare costs, and benefit society by getting people back to work and caring for their families.

**Examples:**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osteoarthritis</td>
<td>No 1 cause of disability in the UK, osteoarthritis costs around 1% of the annual GNP</td>
</tr>
<tr>
<td></td>
<td>31% of women and 42% of men who receive artificial hips are working age</td>
</tr>
<tr>
<td></td>
<td>£37.4 million of welfare savings each year from patients returning to work</td>
</tr>
<tr>
<td>Obstructive Sleep Apnoea</td>
<td>1 in 20 UK adults has OSA, a gateway to other conditions including stroke, diabetes and depression</td>
</tr>
<tr>
<td></td>
<td>20% of UK road accidents are due to OSA; fatal accidents cost on average £1m to public services</td>
</tr>
<tr>
<td></td>
<td>Increased awareness and treatment of OSA could save the NHS £28m and prevent 10,000 road accidents each year</td>
</tr>
<tr>
<td>Diabetes</td>
<td>3.5 million people in the UK are affected by Type 1 and 2 diabetes</td>
</tr>
<tr>
<td></td>
<td>Deaths from diabetes complications will double by 2030</td>
</tr>
<tr>
<td></td>
<td>£62 million potential annual savings from hospital and consultant visits by increasing insulin pumps to NICE benchmark</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>No 1 cause of death in the UK, costing the NHS £629m a year in direct costs, and around £350m in social care</td>
</tr>
<tr>
<td></td>
<td>Over 1 million people of working age with coronary heart disease by 2030</td>
</tr>
<tr>
<td></td>
<td>75,000 angioplasty procedures are performed in England every year, improving patients’ quality of life, and reducing future hospitalisations</td>
</tr>
</tbody>
</table>

**Medical Technology**

- Saves the NHS millions every year in avoided costs.
- Speeds up diagnosis and ensures people get the right care for them.
- Can improve patients’ quality of life instantly.
- Gets people back to work and caring for their families.
- Has the potential to drastically cut the UK’s £41bn annual sickness welfare bill.

The Medical Technology Group (MTG) is a coalition of patient groups, research charities and medical device manufacturers working together to make medical technologies available to everyone who needs them.

Sources: Arthritis and Musculoskeletal Alliance; Arthritis Research Campaigns; British Lung Foundation; Cancer UK; Department of Health; HM Treasury; National Economic Research Associates; NHS; Office for National Statistics (ONS); Royal College of Surgeons; Stroke; The Work Foundation; World Health Organization.
MTG Members

<table>
<thead>
<tr>
<th>ABHI</th>
<th>INPUT</th>
</tr>
</thead>
<tbody>
<tr>
<td>AdvaMed</td>
<td>Insightec</td>
</tr>
<tr>
<td>AntiCoagulation Europe</td>
<td>International Alliance of Patients’ Organizations</td>
</tr>
<tr>
<td>ARMA</td>
<td>Intuitive Surgical</td>
</tr>
<tr>
<td>Arrhythmia Alliance</td>
<td>JDRF</td>
</tr>
<tr>
<td>Arthritis Care</td>
<td>Johnson &amp; Johnson</td>
</tr>
<tr>
<td>Atrial Fibrillation Association</td>
<td>Lindsay Leg Club</td>
</tr>
<tr>
<td>BD</td>
<td>Medtronic</td>
</tr>
<tr>
<td>British Kidney Patient Association</td>
<td>National Rheumatoid Arthritis Society</td>
</tr>
<tr>
<td>Bladder and Bowel Foundation</td>
<td>Nevro</td>
</tr>
<tr>
<td>Boston Scientific</td>
<td>Pancreatic Cancer UK</td>
</tr>
<tr>
<td>British Cardiac Patients Association</td>
<td>Pelvic Pain Support Network</td>
</tr>
<tr>
<td>C R Bard</td>
<td>Pumping Marvellous</td>
</tr>
<tr>
<td>Cardiomyopathy UK</td>
<td>Roche Diagnostics</td>
</tr>
<tr>
<td>Coloplast UK</td>
<td>SADS UK</td>
</tr>
<tr>
<td>Diabetes UK</td>
<td>Smith &amp; Nephew</td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>Smiths Medical</td>
</tr>
<tr>
<td>Eucomed</td>
<td>St Jude Medical</td>
</tr>
<tr>
<td>FABLE</td>
<td>STARS</td>
</tr>
<tr>
<td>FEmISA</td>
<td>Stryker</td>
</tr>
<tr>
<td>Group B Strep Support</td>
<td>The Circulation Foundation</td>
</tr>
<tr>
<td>Heart Research UK</td>
<td>The Patients Association</td>
</tr>
<tr>
<td>Heart Valve Voice</td>
<td>The Somerville Foundation</td>
</tr>
<tr>
<td>ICD Group</td>
<td></td>
</tr>
</tbody>
</table>